Europe Is Quietly Winning the Clinical Trial Race

Good morning, ! Today we’re covering healthcare’s renewed focus on outbreak containment, private equity’s continued bet on healthcare staffing infrastructure, Europe’s growing advantage in clinical trial density, and the operational race to build faster, more resilient healthcare systems worldwide.

Want to advertise in Healthcare 150? Check out our ad platform, here.

Know someone in the healthcare space who should see this? Forward it their way. Here’s the link.

— The Healthcare150 Team

MICROSURVEY

HEADLINE OF THE WEEK

Healthcare Relearns Outbreak Containment

The hantavirus outbreak tied to the Hondius cruise ship is small in scale, but it is exposing a familiar operational vulnerability: healthcare systems still struggle to rapidly adapt frontline protocols when dealing with emerging infectious threats.

A Dutch hospital quarantined 12 staff members after blood and urine from an infected patient were handled without the strictest containment procedures. The WHO has now confirmed 9 total cases, warning that more could emerge due to the virus’s long incubation period. Importantly, officials continue to stress this is not another COVID-style event.

The bigger signal is operational, not epidemiological. Hospitals spent years building pandemic infrastructure, but this incident highlights how execution gaps still appear when protocols shift quickly under uncertainty. Even low-transmission pathogens can trigger staffing disruptions, workflow friction, and reputational risk if containment standards are inconsistently applied.

Why it matters: healthcare biosecurity is increasingly becoming an operational competency, not just a public health issue. For providers, preparedness now extends beyond PPE stockpiles toward rapid protocol deployment, workforce compliance, and infectious disease response systems that can scale without disrupting care delivery. (More)

PRESENTED BY EXACT INSIGHT

95%+ qualified. 80%+ recontact. Built for live PE research.

When diligence moves fast, the quality of the respondent matters as much as the speed of the match.

Exact Insight helps PE teams generate more reliable primary research with 95%+ qualification rates, 80%+ recontact success, and access to vetted B2B professionals, healthcare experts, and global consumer panels. Quant, qual, and hybrid studies are built around the specific question at hand and delivered fast enough for live deal and portfolio workflows.

So whether you are pressure-testing a thesis, sizing a market, or validating a niche operator segment, you get cleaner inputs and a research process you can build on.

Scope a Diligence Project →

DEAL OF THE WEEK

Cross Country Gets a Second Dance Partner

Cross Country Healthcare is heading back to the altar — this time with private equity firm Knox Lane, which agreed to acquire the healthcare staffing company for $437 million in an all-cash deal. The price tag values Cross Country at $13.25 per share, a 31% premium to its prior close and, notably, well below the $615 million valuation offered by Aya Healthcare before regulators pulled out the antitrust flamethrower last year.

The backdrop matters. During COVID, travel nurses became healthcare’s version of surge pricing at a Taylor Swift concert: expensive, unavoidable, and deeply controversial. Regulators worried that combining two of the country’s largest staffing firms would give Aya too much leverage over already cash-strapped hospitals.

Enter Knox Lane. PE firms don’t trigger the same competitive alarm bells, which makes this deal feel less like a strategic merger and more like a regulatory workaround with better optics. Timing also helped: Cross Country’s latest earnings showed revenue down 18% YoY and widening losses, turning the company from growth story into operational turnaround.

The bigger picture: Healthcare staffing may have cooled from pandemic highs, but labor shortages haven’t disappeared. PE clearly still sees value in the infrastructure behind healthcare labor — even if the gold rush phase is over. (More)

REGIONAL FOCUS

Europe’s Clinical Trial Density Advantage

The global clinical trial map still tilts heavily toward the U.S., which leads with 4,034 active trials, more than 3x China’s total. But the more important signal sits beneath the surface: Europe is outperforming on trial density, not scale. France, the UK, and Spain each run materially more trials per capita than the U.S., with Spain reaching 17.79 trials per 100K people versus just 1.16 in the U.S.

That matters because trial concentration increasingly reflects regulatory efficiency, patient recruitment speed, and infrastructure quality, not just pharma spending. Europe’s harmonized regulatory environment and integrated public health systems continue to lower operational friction for multinational studies, particularly in oncology and rare disease research.

Meanwhile, China’s rise remains volume-driven rather than ecosystem-driven. The country now ranks second globally with 1,215 trials, supported by faster approvals and massive patient pools. But its per-capita intensity remains low at 0.08 per 100K, suggesting scale has not yet translated into the same research saturation seen across Western Europe.

For sponsors and CROs, the implication is becoming clearer: the next competitive edge in clinical development is less about where trials are cheapest, and more about where they can scale quickly with regulatory predictability and high-quality data capture. (More)

INTERESTING ARTICLES

"Don’t watch the clock; do what it does. Keep going."

Sam Levenson